OutSee
OutSee is a Cambridge-based AI genomics company whose Nomaly platform predicts disease and identifies therapeutic targets directly from genomic data, serving pharmaceutical and biotech partners pursuing CNS, rare, metabolic, and ALS drug discovery programs through co-development and licensing collaborations.
- Company typePrivate
- Founded2022
- HeadquartersCambridge, United Kingdom
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What OutSee does
OutSee Limited is a Cambridge, UK-based computational genomics company founded in 2022 that builds AI-driven methods for therapeutic target identification and precision medicine. Its core product is Nomaly, a proprietary AI engine that predicts disease and phenotype directly from a single genome ab initio by reasoning from molecular and cell biology fundamentals rather than pattern-matching known genetic associations. The platform is positioned to complement rather than replace existing genomic methods, with claimed advantages in extracting signal from small or complex cohorts, multi-variant effects, and mechanistically cooperative genetic interactions that confound traditional association-based approaches. OutSee initially targets pharmaceutical and biotech customers developing therapeutics in CNS disorders, rare diseases, and metabolic conditions, with ALS added in 2026 via the Longitude Prize on ALS Discovery Award.
OutSee operates a B2B, partnership-driven business model. Revenue is generated through strategic collaborations, co-development agreements, and licensing arrangements with pharma, biotech, and preclinical CROs. The company's most significant commercial relationship to date is a January 2026 strategic collaboration with o2h discovery to build a library of drug candidates against OutSee's lead AI-identified therapeutic target, funded by o2h through its InflexionRx program. OutSee is also advancing non-commercial work through a research collaboration with Dr Martin Turner's group at the University of Oxford under the Longitude Prize on ALS.
The company has raised approximately £4.4M across two seed rounds (£1.8M in June 2025 and £2.5M in January 2026, both led by Ahren Innovation Capital) plus a £100,000 Discovery Award from the Longitude Prize on ALS in May 2026. It is led by founder and CEO Julian Gough and operates with a 1-10 person team. As of the latest available data, OutSee is private, has no disclosed revenue, and has not announced any acquired customers beyond its named partners.
OutSee firmographics
Firmographics- Name
- OutSee
- Legal name
- OutSee Limited
- Website
- https://outsee.co.uk
- Company type
- Private
- Founded year
- 2022
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- OutSee is a Cambridge-based AI genomics company whose Nomaly platform predicts disease and identifies therapeutic targets directly from genomic data, serving pharmaceutical and biotech partners pursuing CNS, rare, metabolic, and ALS drug discovery programs through co-development and licensing collaborations.
- Ownership category
- akta.pro rank
OutSee industry classification
Industry- Product category
- AI-powered genomics drug discovery software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (5132)
- SIC
- Services-Computer Programming, Data Processing, Etc. (7370), Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF)
Keywords
Where OutSee is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
OutSee business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Strategic partnerships and collaborations: OutSee generates revenue through strategic partnerships with pharmaceutical and biotech companies, including collaborative drug discovery programs and co-development agreements where partners fund research activities.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
OutSee product offering
Product offeringCore offering
OutSee develops Nomaly, a predictive AI engine that predicts disease and phenotype directly from a single genome ab initio, enabling pharmaceutical and biotech partners to identify therapeutic targets and build drug candidate libraries. The platform works on small and large datasets, common and rare variation, and is initially applied to CNS disorders, rare diseases, and metabolic conditions.
Product overview
OutSee is a genomics and drug discovery company that offers a single unified AI platform called Nomaly. This platform serves as the core technology for predictive genomics and drug target discovery. OutSee also provides drug discovery services to partners, using the Nomaly platform to identify therapeutic targets and build libraries of drug candidates for pharmaceutical and biotech collaborations.
Differentiator
Problem solved
Functional benefit
Brands
- Nomaly: AI-powered predictive genomics engine that predicts disease and phenotype directly from a single genome ab initio, using fundamental molecular and cell biology rather than pattern-matching known genetic associations.
Products and services
- Nomaly Nomaly is OutSee's AI engine that predicts disease and phenotype directly from a single genome ab initio. Rather than pattern-matching known genetic associations, it uncovers underlying biological mechanisms that drive and modulate disease using fundamental molecular and cell biology, working on small and large datasets, common and rare variation, and common and rare diseases. It is offered to pharmaceutical and biotech partners for therapeutic target discovery, precision medicine patient grouping, and analysis of smaller cohorts.
Quantifiable outcome
- Successfully identified lead AI-identified target candidates for validation
Companies that use OutSee
Customer profileSegments4 records
Ideal customer profiles1 record
OutSee technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature1 record
OutSee partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- Longitude Prize on ALScoreOutSee selected for Discovery Award providing £100,000 funding and access to genomic data from 9,000 ALS patients. OutSee will analyze this data using its Nomaly platform over nine months to identify new therapeutic targets for ALS treatment as part of a competitive £7.5 million global challenge prize.
- University of Oxford (Dr Martin Turner's group)coreResearch partnership with Dr Martin Turner's group at the University of Oxford as part of the Longitude Prize on ALS Discovery Award program to analyze genomic data and identify therapeutic targets for ALS.
- o2h discoverycoreStrategic collaboration agreement for joint drug discovery program focused on OutSee's lead AI-identified target candidate. o2h discovery, a preclinical CRO, will fund the collaboration through its InflexionRx partnership program and help build a library of drug candidates for OutSee's lead target using OutSee's Nomaly platform.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
OutSee competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: AI-driven drug discovery company using high-throughput biology and ML to identify novel targets and advance programs through preclinical and clinical stages. Closely comparable business model (AI for target ID and early discovery) targeting similar pharma and biotech customers.
- BenevolentAI: London-headquartered AI drug discovery company that combines biomedical knowledge graphs and machine learning to identify new therapeutic targets. Directly comparable to OutSee as a UK-based AI target-discovery platform selling into pharma partnerships, though at a more mature stage.
- Isomorphic Labs: Alphabet-founded AI drug discovery company applying DeepMind's protein structure and generative biology models to pharma partnerships. A direct competitor in AI-driven target and drug discovery with substantially more capital and pharma deals.
- Exscientia: Oxford-based AI drug discovery company using AI platforms to design and develop new medicines with pharma partners. Strong UK peer with similar pharma partnership GTM and AI-first discovery approach.
- Insitro: Machine learning-driven drug discovery company combining induced pluripotent stem cell biology with ML to discover targets and develop therapeutics. Comparable in building predictive AI/ML platforms for pharmaceutical R&D and forming pharma partnerships.
Emerging players
- Congenica: Cambridge, UK-based clinical genomics and bioinformatics company providing genomic data analysis for rare disease and precision medicine. UK regional peer applying AI/bioinformatics to genomic interpretation, adjacent to OutSee's genomics-led discovery use cases.
- Eagle Genomics: Cambridge-based bioinformatics platform company applying AI and network science to microbiome and multi-omics data for life sciences R&D. UK peer offering life science informatics and analytics, adjacent to OutSee's multi-omics and target discovery positioning.
- Relation Therapeutics: UK-based ML-driven drug discovery company focused on using machine learning on genetic and phenotypic data to identify novel therapeutic targets. Highly comparable in approach (genetics-first AI target discovery) and stage.
Broad incumbents
- Schrödinger: Established computational chemistry and predictive analytics platform serving pharma with molecular simulation, predictive modeling, and discovery software. A broader incumbent offering computational drug discovery tooling overlapping with OutSee's predictive AI positioning.
Regional players
- Genomics PLC: UK-based genomics data and analytics company applying population-scale genetic insights to drug target discovery and precision medicine. Comparable in genomics-led target identification from UK, though more focused on data analytics than a discovery engine.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights7 records
Customer concentration
OutSee social profiles
Digital presenceOutSee financial estimates
Financial estimateRevenue estimate
Valuation estimate
OutSee leadership team
Management profileNumber of profiles
Profiles1 record
OutSee funding detail
Funding detailFunding overview
Funding rounds2 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
OutSee M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about OutSee
What does OutSee do?
OutSee develops Nomaly, a predictive AI engine that predicts disease and phenotype directly from a single genome ab initio, enabling pharmaceutical and biotech partners to identify therapeutic targets and build drug candidate libraries. The platform works on small and large datasets, common and rare variation, and is initially applied to CNS disorders, rare diseases, and metabolic conditions.
Is OutSee a public or private company?
OutSee is a private company. It is classified as venture growth investor backed and is currently operating.
When was OutSee founded?
OutSee was founded in 2022. It employs 1 to 10 people.
Where is OutSee based?
OutSee is headquartered in Cambridge, United Kingdom, in the Europe region.
How does OutSee make money?
One revenue line is on record: strategic partnerships and collaborations.
Who are OutSee's main competitors?
Direct peers on record are Recursion Pharmaceuticals, BenevolentAI, Isomorphic Labs, Exscientia and Insitro. Emerging players are Congenica, Eagle Genomics and Relation Therapeutics. Schrödinger is listed as a broad incumbent. Genomics PLC is listed as a regional player.
Does OutSee have an API?
No public API is recorded for OutSee.
What industry is OutSee in?
OutSee's product category is AI-powered genomics drug discovery software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 7370.